An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington’s disease appears to be safe and may improve cognition. That is the conclusion of a study published today in the Archives of Neurology.
“This is the first clinical trial that has focused on what is perhaps the most disabling aspect of the disease,” said University of Rochester Medical Center neurologist Karl KieburtzM.D.the lead author of the study. “While more investigation needs to be donethese results are encouraging and showfor the first timea statistically significant benefit in terms of improved cognitive function in patients with Huntington’s disease.”
Huntington’s disease is a progressive neurodegenerative disorder that impacts movementbehaviorcognitionand generally results in death within 20 years of the disease’s onset. The disease steadily erodes a person’s memory and their ability to think and learn. Over timethis cognitive impairment contributes to the loss of the ability to work and perform the activities of daily life. There are no treatments currently available that effectively alter the course of the disease or improve cognition.
An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington’s disease appears to be safe and may improve cognition. That is the conclusion of a study published today in the Archives of Neurology.
“This is the first clinical trial that has focused on what is perhaps the most disabling aspect of the disease,” said University of Rochester Medical Center neurologist Karl KieburtzM.D.the lead author of the study. “While more investigation needs to be donethese results are encouraging and showfor the first timea statistically significant benefit in terms of improved cognitive function in patients with Huntington’s disease.”
Huntington’s disease is a progressive neurodegenerative disorder that impacts movementbehaviorcognitionand generally results in death within 20 years of the disease’s onset. The disease steadily erodes a person’s memory and their ability to think and learn. Over timethis cognitive impairment contributes to the loss of the ability to work and perform the activities of daily life. There are no treatments currently available that effectively alter the course of the disease or improve cognition.